← 홈

혈액암 (AML/ALL)

858개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 858개
AntibodyRochePreclinical

atezolizumab (Tecentriq, Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Preclinical#항체#면역항체+2
효능 ORR 88.7%임상시험 18상태 RECRUITING
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Ifinatamab deruxtecan (Ifinatamab deruxtecan)

Prostate Cancer; Prostatic Neoplasms · Small Cell Lung Cancer

#SmallCellLungCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 18상태 RECRUITING
AntibodystaleRochePhase 3

Rituximab and Hyaluronidase Human (Rituximab and Hyaluronidase Human)

Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 9%임상시험 18상태 RECRUITING
ADCBiologicstaleMabwell (Shanghai) Bioscience C…Phase 3

9MW2821 (9MW2821)

Locally Advanced or Metastatic Triple-negative Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 RECRUITING
ADCBiologicstaleEli Lilly and CompanyPhase 3

MIRV (MIRV)

Ovarian Neoplasms; Fallopian Tube Neoplasms · Ovarian Neoplasms

#OvarianNeoplasms#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 51.9%임상시험 17상태 RECRUITING
CGTBiologicstaleStephan Grupp MD PhDPhase 1

BEAM-201 (Allogeneic anti-CD7 CAR-T cells, Allogeneic anti-CD7 CAR-T cells (BEAM-201))

T-Cell Acute Lymphoblastic Leukemia/Lymphoma · T-Cell Acute Lymphoblastic Leukemia/Lymp

#T-CellAcuteLymphoblasticLeukemia#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 16상태 RECRUITING
CGTBiologicstaleDutch Cancer SocietyPhase 1

UCB-NK cells (UCB-NK cells)

Recurrent Ovarian Carcinoma; Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma

#RecurrentOvarianCarcinoma#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 16상태 ACTIVE
CGTBiologicLiping DouPhase 2

CD22/CD19 Dual-Target CAR-T Cells (CD22/CD19 Dual-Target CAR-T Cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 15상태 RECRUITING
ADCBiologicstaleShanghai Junshi Bioscience Co.,…Phase 2

JS207 (JS207)

Non-squamous Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

Danvatirsen (Danvatirsen)

Advanced Colorectal Carcinoma; Advanced Lung Non-Small Cell Carcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 11.1%임상시험 14상태 RECRUITING
CGTBiologicstaleChina Immunotech (Beijing) Biot…Phase 1

EBV-TCR-T cells (EBV-TCR-T cells)

EBV-associated Hemophagocytic Lymphohistiocytosis; EBV Infection · EBV Infection After Allogenic HSCT

#EBVInfectionAfterAllogenicHSCT#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 14상태 ACTIVE
ADCBiologicstaleArcus Biosciences, Inc.Phase 2

Quemliclustat (Quemliclustat)

Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis Urothelial Carcinoma · Prostatic Neoplasms, Castration-Resistan

#ProstaticNeoplasmsCastration-Res#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 14상태 RECRUITING
AntibodystaleBayerPhase 2

anetumab ravtansine (anetumab ravtansine)

Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma · Pancreatic Cancer

#PancreaticCancer#Antibody#Phase2#항체#면역항체+4
효능 ORR 7.2%임상시험 14상태 DISCONTINUED
CGTBiologicStephan Grupp MD PhDPhase 2

huCART19 (Autologous, humanized anti-CD19 CAR T cell therapy, Autologous, humanized anti-CD19 CAR T cell therapy (huCART19))

B-cell Acute Lymphoblastic Leukemia; B Lineage Lymphoblastic Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 13상태 RECRUITING
AntibodystaleAmgenPreclinical

Dasatinib and blinatumomab (Dasatinib and blinatumomab)

Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#Antibody#Preclinical#항체#면역항체+2
효능 ORR 10%임상시험 13상태 ACTIVE
ADCBiologicstaleHoffmann-La RochePhase 3

Divarasib (Divarasib)

Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer · Solid Tumors

#SolidTumors#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING
AntibodystaleStemcentrxPhase 1

Rovalpituzumab Tesirine (Rovalpituzumab Tesirine)

Small Cell Lung Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase1#항체#면역항체+3
효능 ORR 27.6%임상시험 13상태 ACTIVE
ADCBiologicAbbVieadizutecanPhase 2

Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Metastatic Colorectal Cancer · Non Small Cell Lung Carcinoma

#NonSmallCellLungCarcinoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 13상태 RECRUITING
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

Anti-CD33 CAR T-cells (Anti-CD33 CAR T-cells)

Acute Myeloid Leukemia; Recurrent Adult Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 12상태 RECRUITING
CGTBiologicstaleBiohaven Pharmaceuticals, Inc.Phase 1

CIML-NK cell therapy (CIML-NK cell therapy)

Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 12상태 RECRUITING

11 / 43 페이지

← 이전다음 →